A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (FALKON)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05039515 |
|
Recruitment Status :
Recruiting
First Posted : September 9, 2021
Last Update Posted : April 29, 2024
|
Sponsor:
Clementia Pharmaceuticals Inc.
Collaborator:
Ipsen
Information provided by (Responsible Party):
Ipsen ( Clementia Pharmaceuticals Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 30, 2025 |
| Estimated Study Completion Date : | August 30, 2029 |